Actonel Related Published Studies
Well-designed clinical trials related to Actonel (Risedronate)
Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. [2009.07]
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. [2009.04.11]
Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. [2009.04]
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. [2009.03.01]
LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men. [2009.03]
Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study. [2009.02]
Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. [2009.01]
The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study. [2009]
Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance. [2009]
Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women. [2008.08]
Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study. [2008.07]
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. [2008.07]
Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. [2008.06.01]
Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. [2008.06]
Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. [2008.06]
Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: A single-center, single-blind, six-period crossover study in healthy female subjects. [2008.05]
Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. [2008.04]
Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia. [2008.04]
Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. [2008.03]
Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. [2008.03]
Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. [2008.03]
Fracture risk remains reduced one year after discontinuation of risedronate. [2008.03]
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. [2008.01]
Additive effects of glucosamine or risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized 18-month trial. [2008]
Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study. [2007.12]
Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients. [2007.09]
Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial. [2007.09]
Weekly risedronate in kidney transplant patients with osteopenia. [2007.08]
Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. [2007.07]
Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). [2007.06]
Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease. [2007.06]
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. [2007.03.20]
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. [2007.01]
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women. [2007]
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. [2006.11]
Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. [2006.08]
Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. [2006.07]
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. [2006.07]
Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. [2006.06]
Between-meal risedronate does not alter bone turnover in nursing home residents. [2006.05]
Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis. [2006.04]
Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. [2006.03]
Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomised study. [2006.01]
A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. [2006.01]
Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis. [2006.01]
Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. [2006]
Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease. [2006]
Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial. [2005.10]
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. [2005.09.01]
Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. [2005.09]
Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. [2005.09]
Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. [2005.08.08]
The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. [2005.07]
Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women. [2005.05.01]
Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. [2005.05]
Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. [2005.04]
Risedronate therapy for prevention of hip fracture after stroke in elderly women. [2005.03.08]
The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study. [2005.02]
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. [2005.01]
Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. [2005]
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. [2004.12]
Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. [2004.12]
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. [2004.11]
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. [2004.09]
The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. [2004.08]
Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. [2004.07.19]
Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. [2004.05]
Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. [2004.04]
Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. [2004.02]
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. [2004.02]
Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. [2004]
Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. [2003.12]
Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. [2003.11]
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. [2003.06]
Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. [2003.06]
A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). [2003.05]
Risedronate prevents new vertebral fractures in postmenopausal women at high risk. [2003.02]
Pharmacoeconomic analysis of osteoporosis treatment with risedronate. [2003]
Risedronate for the prevention and treatment of postmenopausal osteoporosis. [2003]
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. [2003]
A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. [2002.12]
Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. [2002.11]
14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. [2002.09]
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. [2002.08]
Risedronate reduces the risk of first vertebral fracture in osteoporotic women. [2002]
Tolerability of risedronate in postmenopausal women intolerant of alendronate. [2001.10]
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. [2001.10]
The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water. [2001.07.17]
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. [2001.05]
Risedronate: a clinical review. [2001.02.12]
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. [2001.02.01]
Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration. [2001.02]
Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis. [2001.01]
Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women. [2000.12]
An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. [2000.11]
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. [2000.10]
Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. [2000.09]
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. [2000.06]
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. [2000.05]
Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. [2000.03]
Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. [2000]
|
